CE

Cerus Corporation

CERSHealthcareNASDAQ

Medical Devices · Last scanned Sep 7, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$206.1M
+14.3% YoY
Net Income
-$15.6M
+25.3% YoY
EBITDA
-$5.5M
+45.0% YoY
Free Cash Flow
$875,250

Scan Results

Daily timeframe
3 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 MACD Negative CrossoverHistogram -0.0097, negative momentum
Sep 2 MACD Negative CrossoverHistogram -0.0063, negative momentum
About Cerus Corporation

Cerus Corporation operates as a biomedical products company. The company carries a $521.9M market cap, placing it firmly in the small-cap category. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Where CERS stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, CERS finished 6.12% above its 150-day moving average ($2.45) and 10.17% above its 200-day moving average ($2.36). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is CERS overbought or oversold?

At the September 3, 2026 close, CERS's RSI(14) was 35.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$521.9M
Fwd P/E-518.00
EPS$-0.03
Beta1.80
52W Change+99.2%
ROE-10.8%
Analysis

The company holds $56.3M in cash, though total debt stands at $76.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $875K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -10.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $130.9M (2021) to $206.1M (2025), reflecting a 58% increase over the period.

With a beta above 1.5, CERS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. No single metric tells the full story. Reviewing CERS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms